Adriana M MontaÃ±o

List of Publications by Year
in descending order

59 papers	2,276 citations	172457 29 h-index	214800 47 g-index
69 all docs	69 docs citations	69 times ranked	1551 citing authors

#	Article	IF	Citations
1	Mucopolysaccharidosis Type IVA: Extracellular Matrix Biomarkers in Cardiovascular Disease. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	1
2	Growth patterns in subjects with mucopolysaccharidosis type VII. Molecular Genetics and Metabolism, 2021, 132, S72.	1.1	0
3	Umbilical mesenchymal stem cell-derived extracellular vesicles as enzyme delivery vehicle to treat Morquio A fibroblasts. Stem Cell Research and Therapy, 2021, 12, 276.	5.5	5
4	Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet Journal of Rare Diseases, 2021, 16, 241.	2.7	33
5	Association between mucopolysaccharidosis Type VII and hydrops fetalis. Ultrasound in Obstetrics and Gynecology, 2020, 55, 416-417.	1.7	13
6	Abnormally increased carotid intima media-thickness and elasticity in patients with Morquio A disease. Orphanet Journal of Rare Diseases, 2020, 15, 73.	2.7	5
7	Biodegradable polyethylene glycol hydrogels for sustained release and enhanced stability of rhGALNS enzyme. Drug Delivery and Translational Research, 2020, 10, 1341-1352.	5.8	7
8	Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome. Journal of Clinical Investigation, 2020, 130, 1288-1300.	8.2	2
9	50 Years Ago in T J P. Journal of Pediatrics, 2019, 215, 40.	1.8	1
10	Causal Therapies in Mucopolysaccharidoses: Enzyme Replacement Therapy. Journal of Child Science, 2018, 08, e156-e162.	0.2	3
11	Advances in Mucopolysaccharidoses. Journal of Child Science, 2018, 08, e113-e115.	0.2	0
12	Tailoring the AAV2 capsid vector for bone-targeting. Pediatric Research, 2018, 84, 545-551.	2.3	25
13	Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis type II. Molecular Genetics and Metabolism, 2017, 120, S77.	1.1	0
14	Injectable microgels development for sustained GALNS enzyme replacement therapy for Morquio syndrome type A. Molecular Genetics and Metabolism, 2017, 120, S70.	1.1	0
15	Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. Molecular Genetics and Metabolism, 2017, 120, S78.	1.1	0
16	Carotid intima-media thickness and arterial stiffness are altered in patients with mucopolysaccharidosis type IVA. Molecular Genetics and Metabolism, 2017, 120, S136.	1.1	0
17	Enzyme Replacement Therapy with Elosulfase alfa for Mucopolysaccharidosis IVA (Morquio A) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	8
18	Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II. Biology of Blood and Marrow Transplantation, 2017, 23, 1795-1803.	2.0	80

#	Article	IF	Citations
19	Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. Journal of Inherited Metabolic Disease, 2017, 40, 151-158.	3.6	61
20	Clinical course of sly syndrome (mucopolysaccharidosis type VII). Journal of Medical Genetics, 2016, 53, 403-418.	3.2	133
21	Activity of daily living for Morquio A syndrome. Molecular Genetics and Metabolism, 2016, 118, 111-122.	1.1	25
22	Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Drug Design, Development and Therapy, 2015, 9, 1937.	4.3	62
23	Therapies for the bone in mucopolysaccharidoses. Molecular Genetics and Metabolism, 2015, 114, 94-109.	1.1	81
24	Age-dependent gene expression profile analysis in Morquio syndrome type A mouse cartilage tissue. Molecular Genetics and Metabolism, 2015, 114, S49.	1.1	0
25	Activities of daily living in patients with Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Molecular Genetics and Metabolism, 2015, 114, 161-169.	1.1	42
26	Therapies for the bone in mucopolysaccharidoses. Molecular Genetics and Metabolism, 2015, 114, S116.	1.1	1
27	Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: Early treatment rescues bone lesions?. Molecular Genetics and Metabolism, 2015, 114, 195-202.	1.1	28
28	Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. JIMD Reports, 2014, 21, 1-13.	1.5	36
29	Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses. Metabolites, 2014, 4, 655-679.	2.9	55
30	Enzyme replacement therapy on hypophosphatasia mouse model. Journal of Inherited Metabolic Disease, 2014, 37, 309-317.	3.6	12
31	Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. Journal of Analytical & Bioanalytical Techniques, 2014, s2, 006.	0.6	29
32	Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry. Nihon Masu Sukuriì„ningu Gakkaishi, 2014, 24, 19-37.	1.0	12
33	Newborn screening and diagnosis of mucopolysaccharidoses. Molecular Genetics and Metabolism, 2013, 110, 42-53.	1.1	131
34	Mucopolysaccharidosis IVA: Correlation between genotype, phenotype and keratan sulfate levels. Molecular Genetics and Metabolism, 2013, 110, 129-138.	1.1	54
35	Assessment of bone dysplasia by microâ€€CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. Journal of Inherited Metabolic Disease, 2013, 36, 235-246.	3.6	56
36	Therapies of mucopolysaccharidosis IVA (Morquio A syndrome). Expert Opinion on Orphan Drugs, 2013, 1, 805-818.	0.8	28

#	Article	IF	Citations
37	Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Molecular Genetics and Metabolism, 2012, 107, 161-172.	1.1	32
38	Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Research and Reports in Endocrine Disorders, 2012, 2012, 65.	0.4	51
39	Impairment of Body Growth in Mucopolysaccharidoses. , 2012, , 2091-2117.		15
40	Evolutionary origin of peptidoglycan recognition proteins in vertebrate innate immune system. BMC Evolutionary Biology, 2011, 11, 79.	3.2	29
41	Comparison of Liquid Chromatographyâ€“Tandem Mass Spectrometry and Sandwich ELISA for Determination of Keratan Sulfate in Plasma and Urine. Biomarker Insights, 2011, 6, BMI.S7451.	2.5	38
42	Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. Journal of Inherited Metabolic Disease, 2010, 33, 141-150.	3.6	59
43	Adenoâ€associated virus gene transfer in Morquioâ€ƒA diseaseâ€ƒâ€“â€ƒeffect of promoters and sulfataseâ€modifying factorâ€ƒ1. FEBS Journal, 2010, 277, 3608-3619.	4.7	31
44	Enhancement of Drug Delivery: Enzyme-replacement Therapy for Murine Morquio A Syndrome. Molecular Therapy, 2010, 18, 1094-1102.	8.2	77
45	Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Molecular Genetics and Metabolism, 2010, 99, 124-131.	1.1	63
46	Validation of keratan sulfate level in mucopolysaccharidosis type IVA by liquid chromatographyâ€“tandem mass spectrometry. Journal of Inherited Metabolic Disease, 2010, 33, 35-42.	3.6	55
47	Sacral dimple: incidental findings from newborn evaluation (Case Presentation). Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 768-769.	1.5	30
48	Sacral dimple: incidental findings from newborn evaluation (Discussion and Diagnosis). Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 910-912.	1.5	7
49	Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). Human Mutation, 2009, 30, 511-519.	2.5	99
50	Growth charts for patients affected with Morquio A disease. American Journal of Medical Genetics, Part A, 2008, 146A, 1286-1295.	1.2	122
51	Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Molecular Genetics and Metabolism, 2008, 94, 178-189.	1.1	44
52	Identification of a Novel Chondroitin Hydrolase in Caenorhabditis elegans. Journal of Biological Chemistry, 2008, 283, 14971-14979.	3.4	29
53	Enzyme replacement therapy in a murine model of Morquio A syndrome. Human Molecular Genetics, 2007, 17, 815-824.	2.9	89
54	Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Molecular Genetics and Metabolism, 2007, 91, 69-78.	1.1	37

#	Article	IF	Citations
55	Murine model (Galnstm(C76S)slu) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins. Molecular Genetics and Metabolism, 2007, 91, 251-258.	1.1	31
56	Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Analytical Biochemistry, 2007, 368, 79-86.	2.4	109
57	Mucopolysaccharidosis IV (Morquio Syndrome). , 2007, , 433-445.		1
58	Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Human Mutation, 2005, 26, 500-512.	2.5	140
59	Development of MPS IVA mouse (Galnstm(hC79SÂ·mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Human Molecular Genetics, 2005, 14, 3321-3335.	2.9	52